NCT05280314 - Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 21, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

January 31, 2027

Conditions

MelanomaSquamous Cell Carcinoma of Head and Neck

Interventions

DRUG

IO102-IO103

IO102-IO103 is a combination of an indoleamine 2,3-dioxygenase 1 (IDO1) peptide (IO102) and a programmed death-ligand 1 (PD-L1) peptide (IO103), emulsified with an adjuvant (Montanide ISA 51 VG).

DRUG

Pembrolizumab KEYTRUDA®

Pembrolizumab KEYTRUDA® administered intravenously

Trial Locations (15)

23219

RECRUITING

Massey Cancer Center, Richmond

06519

RECRUITING

Yale, New Haven

02215

RECRUITING

Dana Farber Cancer Institute, Boston

Sydney 2060

RECRUITING

Melanoma Institute Australia The Uiniversity of Sydney, and Royal North Shore Hospital, Sydney

3VIC 3000

RECRUITING

Peter MacCallum Cancer Centre, Melbourne

8200 Aarhus

RECRUITING

Aarhus University Hospital, Aarhus

9 DK-2730

RECRUITING

Copenhagen University Hospital Herlev, Copenhagen

59037 Lille

RECRUITING

CHRU Lille, Lille

92104 Boulogne

RECRUITING

Hôpital Ambroise-Paré, Paris

94805 Villejuif

RECRUITING

Institut Gustave Roussy, Paris

D-45147 Essen

RECRUITING

Universitätsklinikum Essen & Research Alliance Ruhr, Essen

69120 Heidelberg

RECRUITING

Universität Heidelberg, Medizinische Fakultät, Heidelberg

08028 Barcelona

RECRUITING

Hospital Universitario Quirón Dexeus, Barcelona

Madrid 28034

RECRUITING

Hospital Universitario Ramón y Cajal, Madrid

46010 Valencia

RECRUITING

Hospital Clínico Universitario de Valencia -INCLIVA, Valencia